Akari Therapeutics To Present A Poster On Pre-Clinical Development Of Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy At The 4th Annual Dry AMD Therapeutic Development Conference
Portfolio Pulse from Benzinga Newsdesk
Akari Therapeutics, Plc (NASDAQ:AKTX) announced that its Chief Scientific Officer will present a poster on the development of PASylated®-Nomacopan for Treatment of Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development conference. The long-acting PAS-nomacopan is in the final stages of pre-clinical development as a potential treatment for GA.
November 06, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akari Therapeutics is presenting its pre-clinical development of PAS-nomacopan as a potential treatment for Geographic Atrophy at a conference. This could potentially boost investor confidence in the company's research and development capabilities.
The presentation of the development of PAS-nomacopan at a conference indicates that the company is making progress in its research and development. This could potentially attract more investors and boost the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100